EAU 2013 - Programme Book - YouMed

Sunday, 17 March
Sponsored Session
17.45 - 19.15 Clinical conundrums in the treatment of metastatic castrationresistant
prostate cancer
Silver Hall - Level N2
Symposium
Chair: P.F.A. Mulders, Nijmegen (NL)
Moderator: C. Hood, London (GB)
Introduction
P.F.A. Mulders, Nijmegen (NL)
Defining disease progression in metastatic CRPC
J.E. Gschwend, Munich (DE)
The role of corticosteroids in the treatment of metastatic CRPC
M. De Santis, Vienna (AT)
C. Parker, London (GB)
Emerging treatment options for the chemotherapy naive patient
P.F.A. Mulders, Nijmegen (NL)
Q&A session. Summary and close
M. De Santis, Vienna (AT)
J.E. Gschwend, Munich (DE)
P.F.A. Mulders, Nijmegen (NL)
C. Parker, London (GB)
Aims and objectives
Recently a number of therapies have been approved providing more options for treatment and improving
outcomes for men with advanced prostate cancer. The satellite symposium sponsored by Janssen
Pharmaceutical Companies of Johnson & Johnson entitled Clinical conundrums in the treatment of metastatic
castration-resistant prostate cancer will address key topics on the management of patients with metastatic
castration-resistant prostate cancer (CRPC) in daily clinical practice. The different definitions of disease
progression in metastatic CRPC, and ways in which progression in the clinic is monitored will be explored.
The role of corticosteroids in the treatment of metastatic CRPC will be considered and the latest data for
androgen biosynthesis inhibition in the pre-chemotherapy setting will also be presented.
Throughout the symposium you will be invited to participate in an interactive activity to provide your views
on key topics in management of patients with metastatic CRPC. A panel discussion is also included in the
program to encourage you to ask questions, exchange ideas, and to share experiences relevant to everyday
clinical practice.
Sponsored by JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
EAU Milan 2013
413
Sponsored Sessions